UK Cardiac Arrhythmia Therapeutics Market Analysis

UK Cardiac Arrhythmia Therapeutics Market Analysis


$ 3999

UK Cardiac Arrhythmia Therapeutics Market valued at $187 Mn in 2022, projected to reach $252 Mn by 2030 with a 3.8% CAGR. The key drivers of this industry include the rising burden of cardiac arrhythmias, increasing focus on preventive care, and technological advancements. The industry is primarily dominated by players such as Abbott, Teva, Bayer, AstraZeneca, Boston Scientific, Sanofi, and Pfizer among others.

ID: IN10GBPH442 CATEGORY: Pharmaceuticals GEOGRAPHY: UK AUTHOR: Riddhi Solanki

Buy Now

UK Cardiac Arrhythmia Therapeutics Market Analysis: Executive Summary

UK Cardiac Arrhythmia Therapeutics Market valued at $187 Mn in 2022, projected to reach $252 Mn by 2030 with a 3.8% CAGR.

Cardiac arrhythmia, also referred to as an irregular heartbeat, is a condition characterized by abnormal heart rhythms that can lead to the heart beating too rapidly, too slowly, or in an irregular manner. This can result in various symptoms, including sensations of fluttering, pounding, or a racing heartbeat. A wide array of factors, such as heart disease, high blood pressure, diabetes, smoking, excessive alcohol or caffeine consumption, stress, and certain medications, can contribute to the occurrence of arrhythmias. Treatment options for cardiac arrhythmia encompass medication, cardioversion, catheter ablation, pulmonary vein isolation, and implantable devices like pacemakers and defibrillators. In certain cases, surgery may be recommended. Companies such as Abbott, Medtronic, Philips, Hillrom, Nuubo, and others are involved in the manufacturing of these treatments. The market for cardiac arrhythmia therapeutics is experiencing growth, driven by innovative pharmaceuticals and the expansion of non-invasive therapeutic methods.

The estimated prevalence of atrial fibrillation is around 1 in every 46 individuals affecting around 1.5 Mn individuals in the UK. The market is being propelled by significant factors such as the surge in the prevalence of cardiac arrhythmias, increasing focus on preventive care, and technological advancements in the therapeutic industry. However, conditions such as adverse side effects of existing treatments and limited reimbursement restrict the growth and potential of the market.

UK cardiac arrhythmia therapeutics market

Market Dynamics

Market Growth Drivers

Rising prevalence of CVDs: The prevalence of cardiac arrhythmias, such as atrial fibrillation (AFib), is increasing in the UK, affecting about 1 in every 45 people and more than 1.5 Mn of the total population. It is driven by factors such as the escalating rates of obesity, hypertension, and a rapidly aging population. The UK is experiencing a notable demographic shift, marked by a significant increase in the population aged over 65, a group more prone to developing arrhythmias. This expanding demographic contributes to a larger market for therapeutics targeting arrhythmias.

Focus on preventive care: Growing efforts in public awareness campaigns and governmental initiatives and organizations such as the British Heart Foundation, advocating for arrhythmia screening programs are resulting in the identification of cases at earlier stages. The early recognition facilitates prompt intervention, potentially averting complications and consequently fueling the demand for diagnostic tools and preventive medications.

Technological advancements: The advancement of minimally invasive ablation methods, exemplified by techniques like catheter ablation for arrhythmias, presents benefits such as reduced hospitalization durations and quicker recovery periods. This enhances patient preferences and stimulates market growth. Ongoing research and development activities are yielding innovative arrhythmia treatments, including gene editing and personalized medicine strategies. These breakthroughs show potential for heightened treatment effectiveness and decreased side effects, capturing patient attention and fostering the expansion of the market.

Market Restraints

Side effects of treatments: Cardiac arrhythmias are complex conditions, and even widely recognized medications pose risks of side effects, such as proarrhythmic events, which can elevate existing arrhythmias. This can result in poor patient adherence or treatment non-compliance. Due to these safety considerations, there is an inclination towards more stringent regulatory standards for the approval of new drugs. This heightened scrutiny makes it increasingly difficult and costly for manufacturers to introduce innovative therapies to the market.

Limited reimbursement: The National Institute for Health and Care Excellence (NICE) holds a pivotal role in influencing drug reimbursement decisions in the UK. The rigorous cost-effectiveness assessments conducted by NICE have the potential to result in reduced prices for medications used in treating arrhythmia. This can have an impact on the profits of drug manufacturers and may pose a constraint on their willingness to invest in innovative solutions.

Healthcare Policies and Regulatory Landscape

In the UK, the regulatory authority responsible for overseeing therapeutics, including medicines and medical devices, is the Medicines and Healthcare Products Regulatory Agency (MHRA). The MHRA plays a crucial role in ensuring the safety, efficacy, and quality of therapeutic products available in the UK market.

To obtain licensure for a therapeutic product, manufacturers must undergo a rigorous evaluation process conducted by the MHRA. This process involves the submission of comprehensive data on the product's safety, efficacy, and quality, including results from clinical trials.  If the product successfully passes the evaluation, the MHRA grants a marketing authorization, allowing the product to be legally marketed and sold in the UK.

For new entrants into the therapeutics market in the UK, the regulatory landscape can be challenging. Companies must navigate complex regulatory requirements, invest significantly in research and development, and demonstrate the safety and efficacy of their products through rigorous testing. The environment for new entrants is influenced by the need for compliance with regulatory standards, the ability to demonstrate product effectiveness, and the capacity to meet the high-quality standards set by the MHRA.

Competitive Landscape

Key Players

  • Abbott
  • Pfizer
  • AstraZeneca
  • Bayer
  • Johnson & Johnson
  • Merck
  • Boston Scientific
  • Medtronic
  • Sanofi
  • Teva Pharmaceuticals

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

UK Cardiac Arrhythmia Therapeutics Market Segmentation

By Test Equipment

  • Electrocardiogram (ECG)
  • Holter monitor
  • Others

By Site of Origin

  • Atrial Fibrillation
  • Sinus Bradycardia
  • Atrial Tachycardia
  • Atrial Flutter
  • Premature Atrial Contractions (PACS)
  • Others

By Type

  • Supraventricular Tachycardias
  • Ventricular Arrhythmias
  • Bradyarrhythmia’s

By Drug Type

  • Antiarrhythmic drugs
  • Calcium channel blockers
  • Beta-blockers
  • Anticoagulants
  • Others

By Mode of Administration

  • Injectable
  • Oral
  • Others

By Distribution channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 23 April 2024
Updated by: Bhanu Pratap Singh

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up